[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA02004671A - Conjugados de interferon gamma. - Google Patents

Conjugados de interferon gamma.

Info

Publication number
MXPA02004671A
MXPA02004671A MXPA02004671A MXPA02004671A MXPA02004671A MX PA02004671 A MXPA02004671 A MX PA02004671A MX PA02004671 A MXPA02004671 A MX PA02004671A MX PA02004671 A MXPA02004671 A MX PA02004671A MX PA02004671 A MXPA02004671 A MX PA02004671A
Authority
MX
Mexico
Prior art keywords
polypeptide
interferon gamma
amino acid
conjugate
conjugates
Prior art date
Application number
MXPA02004671A
Other languages
English (en)
Inventor
Karsten Hansen Christian
Original Assignee
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd filed Critical Maxygen Holdings Ltd
Publication of MXPA02004671A publication Critical patent/MXPA02004671A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se expone un conjugado que exhibe una actividad interferon gamma y comprende al menos una primera entidad no polipeptidica enlazada covalentemente con un polipeptido de IFG. El polipeptido comprende una secuencia de aminoacidos que difiere de aquella de un polipeptido de IFNG original en al menos un residuo de aminoacido introducido y/o al menos eliminado que comprende un grupo de union para la entidad sin polipeptido. El conjugado se puede utilizar para el tratamiento de diversas enfermedades.
MXPA02004671A 1999-11-12 2000-11-13 Conjugados de interferon gamma. MXPA02004671A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199901631 1999-11-12
US16629399P 1999-11-18 1999-11-18
DKPA200000447 2000-03-17
PCT/DK2000/000631 WO2001036001A2 (en) 1999-11-12 2000-11-13 Interferon gamma conjugates

Publications (1)

Publication Number Publication Date
MXPA02004671A true MXPA02004671A (es) 2004-09-10

Family

ID=27221366

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02004671A MXPA02004671A (es) 1999-11-12 2000-11-13 Conjugados de interferon gamma.

Country Status (17)

Country Link
US (3) US7232562B2 (es)
EP (1) EP1231943A1 (es)
JP (1) JP2003513681A (es)
KR (1) KR20020065517A (es)
BG (1) BG106790A (es)
BR (1) BR0015506A (es)
CA (1) CA2390292A1 (es)
CZ (1) CZ20021836A3 (es)
HR (1) HRP20020387A2 (es)
HU (1) HUP0203409A3 (es)
IL (2) IL149267A0 (es)
IS (1) IS6367A (es)
MX (1) MXPA02004671A (es)
NO (1) NO20022251L (es)
PL (1) PL356007A1 (es)
SK (1) SK8292002A3 (es)
WO (1) WO2001036001A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
YU32402A (sh) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Konjugati gama interferona
BR0015506A (pt) 1999-11-12 2002-07-23 Maxygen Holdings Ltd Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US6964761B1 (en) 2001-12-12 2005-11-15 New York University Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-γ
CA2470763A1 (en) * 2001-12-18 2003-06-26 Mondobiotech Laboratories Anstalt Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ES2348230T3 (es) 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
WO2004005341A2 (en) * 2002-07-03 2004-01-15 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
CA2496314A1 (en) * 2002-08-27 2004-03-11 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2004099245A1 (de) * 2003-05-05 2004-11-18 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Stabilisiertes interferon-ϝ
EP1633317A4 (en) 2003-05-16 2008-08-20 Intermune Inc Synthetic chemokine receptor ligands and methods of use therefor
US20070020252A1 (en) * 2003-08-29 2007-01-25 Ladner Robert C Modified protease inhibitors
JP4739207B2 (ja) * 2003-08-29 2011-08-03 ダイアックス コーポレーション ポリペグ化されたプロテアーゼインヒビター
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
CA2566247A1 (en) * 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
ES2426005T3 (es) 2004-07-23 2013-10-18 Acceleron Pharma Inc. Polipéptidos del receptor ACTRII, procedimientos y composiciones
CA2574953A1 (en) 2004-07-26 2006-02-09 Dow Global Technolgies Inc. Process for improved protein expression by strain engineering
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20200041386A (ko) 2005-11-23 2020-04-21 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
KR20140137463A (ko) 2007-02-01 2014-12-02 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 유방암을 치료 또는 예방하기 위한 이들의 용도
TW202104248A (zh) * 2007-02-02 2021-02-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CA2677605C (en) 2007-02-09 2016-01-19 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth in cancer patients
EP2615172A1 (en) 2007-04-27 2013-07-17 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
EP2195010A4 (en) * 2007-08-21 2012-03-14 Genzyme Corp TREATMENT WITH INHIBITORS OF KALLIKREINE
JP2010539236A (ja) 2007-09-18 2010-12-16 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
EP3845239A1 (en) 2009-06-08 2021-07-07 Acceleron Pharma Inc. Use of anti-actriib proteins for increasing thermogenic adipocytes
KR20190090049A (ko) 2009-06-12 2019-07-31 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
DK2521568T3 (en) 2010-01-06 2018-11-19 Dyax Corp PLASMACALLIC CLEANING PROTEINS
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
RU2018145985A (ru) 2012-11-02 2019-02-18 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EA032740B1 (ru) 2013-10-04 2019-07-31 Энджинеик Молекьюлар Деливери Пти Лтд Способ лечения опухоли у индивидуума и набор для осуществления способа
WO2015148790A1 (en) 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
MX2016016531A (es) 2014-06-13 2017-04-25 Acceleron Pharma Inc Metodos y composiciones para el tratamiento de las ulceras.
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
ES2966888T3 (es) 2014-11-06 2024-04-24 Pharmaessentia Corp Régimen de dosificación para el interferón pegilado
TWI773117B (zh) 2014-12-03 2022-08-01 美商西建公司 活化素-actrii拮抗劑及治療貧血之用途
MX2017015127A (es) * 2015-05-27 2018-06-22 Univ Northwestern Particulas modificadas por carbohidratos y formulaciones en particulas para modular una respuesta inmunitaria.
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP3529264B1 (en) * 2016-10-24 2022-03-09 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
AU2019384145A1 (en) * 2018-11-20 2021-06-10 Innovative Cellular Therapeutics Holdings, Ltd. Modified cell expressing therapeutic agent and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US5582824A (en) 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
JPS58110548A (ja) 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
ZA831094B (en) 1982-02-22 1983-11-30 Biogen Nv Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides
US5004689A (en) 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
IL68100A0 (en) 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4835256A (en) 1982-09-30 1989-05-30 New York University & Juridical Foundation Human gamma interferon polypeptide having glutamine as the ninth n-terminal amino acid
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
WO1984002129A1 (en) 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Human immune interferon protein and process for its preparation
JPH0740925B2 (ja) 1983-03-14 1995-05-10 協和醗酵工業株式会社 新規ヒトインタ−フエロン−γポリペプチド
US4604284A (en) 1983-09-20 1986-08-05 Hoffmann-La Roche Inc. Homogeneous immune interferon fragment
JPH0788398B2 (ja) 1983-10-17 1995-09-27 サントリー株式会社 新規生理活性ポリペプチドおよびその製造法
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
MX9203641A (es) 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4758656A (en) 1983-12-26 1988-07-19 Kyowa Hakko Kogyo Co., Ltd. Novel human interferon-gamma polypeptide derivative
EP0158198A1 (en) 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
DE3414831A1 (de) 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
US4921698A (en) 1984-05-25 1990-05-01 Asahi Kasei Kogyo Kabushiki Kaisha Polypeptide having gamma-interferon activity lacking amino acids coded by exon 4
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
US4845196A (en) 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
DE3536939A1 (de) 1985-10-17 1987-04-23 Hoechst Ag Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5362490A (en) 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
GB8619725D0 (en) 1986-08-13 1986-09-24 Hoffmann La Roche Homogenous interferon fragments
US5157004A (en) 1986-12-27 1992-10-20 Takeda Chemical Industries, Ltd. Polypeptides and production thereof
JP2653061B2 (ja) 1986-12-27 1997-09-10 武田薬品工業株式会社 新規ポリペプチドおよびその製造法
US4944941A (en) 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
DE3730331A1 (de) 1987-09-10 1989-03-30 Basf Ag Neue polypeptide, verfahren zur herstellung, die vektoren dafuer und arzneimittel daraus
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
BG52073B2 (en) 1990-01-24 1996-04-30 Inst Molekuljarna Biolog Method for the preparation of recombinant human noncystein -interferon, free of n-end methionine
US5241072A (en) * 1990-05-25 1993-08-31 Genzyne Corporation Oligosaccharide oxazolines, oligosaccharide conjugates and methods of preparation thereof
CA2090478A1 (en) 1990-08-31 1992-03-01 Satwant K. Narula Human interferon- 4-134, functional equivalents thereof and methods of using and compositions employing these materials
DE4036856C1 (es) 1990-11-19 1992-05-27 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
KR950014915B1 (ko) 1991-06-19 1995-12-18 주식회사녹십자 탈시알로당단백-포함화합물
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
JPH0770195A (ja) 1993-08-23 1995-03-14 Yutaka Mizushima 糖修飾インターフェロン
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5770191A (en) 1995-05-24 1998-06-23 University Of Florida Active C-terminal peptides of interferon--gamma and their use
DE19535853C2 (de) 1995-09-18 1999-04-01 Fraunhofer Ges Forschung Varianten des rekombinanten humanen Interferon-gamma, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0795332B1 (en) 1996-03-14 2005-06-01 Mondobiotech Interferon SA Medical use of gamma-interferon in interstitial lung diseases
JP2001510033A (ja) * 1997-07-14 2001-07-31 ボルダー バイオテクノロジー， インコーポレイテッド 成長ホルモンおよび関連タンパク質の誘導体
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
EP1221976A4 (en) 1999-09-28 2003-12-03 Amarillo Biosciences Inc IFN-GAMA IN LOW DOSAGE FOR TREATING DISEASES
BR0015506A (pt) 1999-11-12 2002-07-23 Maxygen Holdings Ltd Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças

Also Published As

Publication number Publication date
WO2001036001A3 (en) 2001-11-15
CZ20021836A3 (cs) 2002-08-14
NO20022251L (no) 2002-07-05
US7232562B2 (en) 2007-06-19
PL356007A1 (en) 2004-05-31
US20060194951A1 (en) 2006-08-31
KR20020065517A (ko) 2002-08-13
JP2003513681A (ja) 2003-04-15
WO2001036001A2 (en) 2001-05-25
US20030153046A1 (en) 2003-08-14
IS6367A (is) 2002-04-29
SK8292002A3 (en) 2002-12-03
US20080176323A1 (en) 2008-07-24
US7504237B2 (en) 2009-03-17
BR0015506A (pt) 2002-07-23
NO20022251D0 (no) 2002-05-10
HUP0203409A3 (en) 2005-06-28
IL149267A0 (en) 2002-11-10
HUP0203409A2 (hu) 2003-01-28
EP1231943A1 (en) 2002-08-21
IL149267A (en) 2008-07-08
CA2390292A1 (en) 2001-05-25
BG106790A (bg) 2003-04-30
HRP20020387A2 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
MXPA02004671A (es) Conjugados de interferon gamma.
YU32402A (sh) Konjugati gama interferona
WO2001051510A3 (en) G-csf conjugates
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
IL124411A0 (en) Lipopolyamines as transfection agents and pharmaceutical uses thereof
WO2001015736A3 (en) Interferon-beta conjugates
BG105709A (en) Piperidines as ccr5 modulatiors
DK2016950T3 (da) Farmaceutisk sammensætning omfattende et exendin-4-peptid
EP2186902A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
GB8922026D0 (en) Novel anti-viral and cytotoxic agent
HK1097449A1 (en) Methods for in vivo delivery of biologics and compositions useful therefor
DE69835201D1 (en) Neoglycoproteine
YU75701A (sh) Farmaceutski preparat
HK1030768A1 (en) Cyclic amino acids and derivatives thereof useful as pharmaceutical agents.
CA2312004A1 (en) Site-specific preparation of polyethylene glycol-grf conjugates
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
IL138665A0 (en) Peptide factor
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
UA65561A (en) Therapeutic agent for lymphatic tumors
EP0683668A4 (en) PREPARATIONS AND METHODS FOR TRANSDERMAL DRUG ADMINISTRATION.
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
TR200200599T2 (tr) İnsan insülini monomerik analogları.
BG103196A (en) Crystalline pharmaceutical product
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
TW323954B (en) Pharmaceutical composition used in the treatment of hypertriglyceridemia, atheroscleorsis and hypercholecterolemia

Legal Events

Date Code Title Description
FG Grant or registration